Literature DB >> 26295436

Nutrient-deprived cancer cells preferentially use sialic acid to maintain cell surface glycosylation.

Haitham A Badr1, Dina M M AlSadek2, Mohit P Mathew3, Chen-Zhong Li4, Leyla B Djansugurova5, Kevin J Yarema6, Hafiz Ahmed7.   

Abstract

Cancer is characterized by abnormal energy metabolism shaped by nutrient deprivation that malignant cells experience during various stages of tumor development. This study investigated the response of nutrient-deprived cancer cells and their non-malignant counterparts to sialic acid supplementation and found that cells utilize negligible amounts of this sugar for energy. Instead cells use sialic acid to maintain cell surface glycosylation through complementary mechanisms. First, levels of key metabolites (e.g., UDP-GlcNAc and CMP-Neu5Ac) required for glycan biosynthesis are maintained or enhanced upon Neu5Ac supplementation. In concert, sialyltransferase expression increased at both the mRNA and protein levels, which facilitated increased sialylation in biochemical assays that measure sialyltransferase activity as well as at the whole cell level. In the course of these experiments, several important differences emerged that differentiated the cancer cells from their normal counterparts including resistant to sialic acid-mediated energy depletion, consistently more robust sialic acid-mediated glycan display, and distinctive cell surface vs. internal vesicle display of newly-produced sialoglycans. Finally, the impact of sialic acid supplementation on specific markers implicated in cancer progression was demonstrated by measuring levels of expression and sialylation of EGFR1 and MUC1 as well as the corresponding function of sialic acid-supplemented cells in migration assays. These findings both provide fundamental insight into the biological basis of sialic acid supplementation of nutrient-deprived cancer cells and open the door to the development of diagnostic and prognostic tools.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer cell; Lectins; Metabolism; Nutrient deprivation; Sialic acid; Surface sensing

Mesh:

Substances:

Year:  2015        PMID: 26295436      PMCID: PMC4658327          DOI: 10.1016/j.biomaterials.2015.08.020

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  44 in total

1.  Metabolic flux increases glycoprotein sialylation: implications for cell adhesion and cancer metastasis.

Authors:  Ruben T Almaraz; Yuan Tian; Rahul Bhattarcharya; Elaine Tan; Shih-Hsun Chen; Matthew R Dallas; Li Chen; Zhen Zhang; Hui Zhang; Konstantinos Konstantopoulos; Kevin J Yarema
Journal:  Mol Cell Proteomics       Date:  2012-03-28       Impact factor: 5.911

2.  Effective glycoanalysis with Maackia amurensis lectins requires a clear understanding of their binding specificities.

Authors:  Christoph Geisler; Donald L Jarvis
Journal:  Glycobiology       Date:  2011-08       Impact factor: 4.313

Review 3.  Lectin approaches for glycoproteomics in FDA-approved cancer biomarkers.

Authors:  Haitham A Badr; Dina M M Alsadek; Ashraf A Darwish; Abdelaleim I Elsayed; Bakhytzhan O Bekmanov; Elmira M Khussainova; Xueji Zhang; William C S Cho; Leyla B Djansugurova; Chen-Zhong Li
Journal:  Expert Rev Proteomics       Date:  2014-03-10       Impact factor: 3.940

Review 4.  O-GlcNAc signalling: implications for cancer cell biology.

Authors:  Chad Slawson; Gerald W Hart
Journal:  Nat Rev Cancer       Date:  2011-08-18       Impact factor: 60.716

Review 5.  Regulation of the metastatic cell phenotype by sialylated glycans.

Authors:  Matthew J Schultz; Amanda F Swindall; Susan L Bellis
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

6.  Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis.

Authors:  Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya; Sabina Kaczanowska; Eduardo Davila; Keyata Thompson; Stuart S Martin; Dhananjaya V Kalvakolanu; Gerardo R Vasta; Hafiz Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-11       Impact factor: 11.205

7.  Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.

Authors:  Te-Chun Hsia; Chih-Yen Tu; Yun-Ju Chen; Ya-Ling Wei; Meng-Chieh Yu; Sheng-Chie Hsu; Shing-Ling Tsai; Wen-Shu Chen; Ming-Hsin Yeh; Chia-Jui Yen; Yung-Luen Yu; Tzung-Chi Huang; Chih-Yang Huang; Mien-Chie Hung; Wei-Chien Huang
Journal:  Mol Pharmacol       Date:  2013-01-25       Impact factor: 4.436

8.  Preferential lectin binding of cancer cells upon sialic acid treatment under nutrient deprivation.

Authors:  Haitham A Badr; Abdelaleim I Elsayed; Hafiz Ahmed; Miriam V Dwek; Chen-Zhong Li; Leyla B Djansugurova
Journal:  Appl Biochem Biotechnol       Date:  2013-08-04       Impact factor: 2.926

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells.

Authors:  Caining Jin; Hasan Rajabi; Sean Pitroda; Ailing Li; Akriti Kharbanda; Ralph Weichselbaum; Donald Kufe
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

View more
  11 in total

Review 1.  Harnessing cancer cell metabolism for theranostic applications using metabolic glycoengineering of sialic acid in breast cancer as a pioneering example.

Authors:  Haitham A Badr; Dina M M AlSadek; Motawa E El-Houseini; Christopher T Saeui; Mohit P Mathew; Kevin J Yarema; Hafiz Ahmed
Journal:  Biomaterials       Date:  2016-11-25       Impact factor: 12.479

2.  Pharmacological, Physiochemical, and Drug-Relevant Biological Properties of Short Chain Fatty Acid Hexosamine Analogues Used in Metabolic Glycoengineering.

Authors:  Christopher T Saeui; Lingshu Liu; Esteban Urias; Justin Morrissette-McAlmon; Rahul Bhattacharya; Kevin J Yarema
Journal:  Mol Pharm       Date:  2017-09-13       Impact factor: 4.939

3.  Cancer cell death induced by nanomagnetolectin.

Authors:  Dina M M AlSadek; Haitham A Badr; Tamer A Al-Shafie; Sabry M El-Bahr; Motawa E El-Houseini; Leyla B Djansugurova; Chen-Zhong Li; Hafiz Ahmed
Journal:  Eur J Cell Biol       Date:  2017-05-10       Impact factor: 4.492

4.  Electrochemical Evaluation of Tumor Development via Cellular Interface Supported CRISPR/Cas Trans-Cleavage.

Authors:  Liangfen Cheng; Fuhan Yang; Longfei Tang; Lelin Qian; Xu Chen; Feng Guan; Juan Zhang; Genxi Li
Journal:  Research (Wash D C)       Date:  2022-04-06

5.  Lectin staining and Western blot data showing differential sialylation of nutrient-deprived cancer cells to sialic acid supplementation.

Authors:  Haitham A Badr; Dina M M AlSadek; Mohit P Mathew; Chen-Zhong Li; Leyla B Djansugurova; Kevin J Yarema; Hafiz Ahmed
Journal:  Data Brief       Date:  2015-10-09

6.  Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis.

Authors:  Chi-Che Hsieh; Yi-Ming Shyr; Wen-Ying Liao; Tien-Hua Chen; Shin-E Wang; Peir-Chuen Lu; Pei-Yu Lin; Yan-Bo Chen; Wan-Yu Mao; Hsin-Ying Han; Michael Hsiao; Wen-Bin Yang; Wen-Shan Li; Yuh-Pyng Sher; Chia-Ning Shen
Journal:  Oncotarget       Date:  2017-01-31

7.  Integration of genetic and metabolic features related to sialic acid metabolism distinguishes human breast cell subtypes.

Authors:  Christopher T Saeui; Alison V Nairn; Melina Galizzi; Christopher Douville; Prateek Gowda; Marian Park; Vrinda Dharmarha; Sagar R Shah; Amelia Clarke; Melissa Austin; Kelley W Moremen; Kevin J Yarema
Journal:  PLoS One       Date:  2018-05-30       Impact factor: 3.240

Review 8.  Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.

Authors:  Emily Rodrigues; Matthew S Macauley
Journal:  Cancers (Basel)       Date:  2018-06-18       Impact factor: 6.639

9.  Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer.

Authors:  Andreia Peixoto; Dylan Ferreira; Rita Azevedo; Rui Freitas; Elisabete Fernandes; Marta Relvas-Santos; Cristiana Gaiteiro; Janine Soares; Sofia Cotton; Beatriz Teixeira; Paula Paulo; Luís Lima; Carlos Palmeira; Gabriela Martins; Maria José Oliveira; André M N Silva; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  J Exp Clin Cancer Res       Date:  2021-06-09

Review 10.  Improving Immunotherapy Through Glycodesign.

Authors:  Matthew J Buettner; Sagar R Shah; Christopher T Saeui; Ryan Ariss; Kevin J Yarema
Journal:  Front Immunol       Date:  2018-11-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.